HIV Prevention Drug Cost Drops to $40/Year – 2027
- A new licensing agreement promises to dramatically increase access to PrEP medication in the United States, lowering the annual cost to approximately $40.
- ViiV Healthcare, a majority-owned company by GlaxoSmithKline, has granted a non-exclusive license to the Medicines Patent Pool (MPP) for dolutegravir, a key component of widely used HIV prevention...
- Currently, a year's supply of PrEP can cost over $20,000 without insurance, creating a significant barrier to access.
“`html
Landmark Agreement: HIV Prevention Drug to Cost $40 Annually in the US Starting 2027
Table of Contents
A new licensing agreement promises to dramatically increase access to PrEP medication in the United States, lowering the annual cost to approximately $40. This development, stemming from a collaboration between ViiV Healthcare and the Medicines Patent Pool, represents a notable step towards ending the HIV epidemic.
What Happened?
ViiV Healthcare, a majority-owned company by GlaxoSmithKline, has granted a non-exclusive license to the Medicines Patent Pool (MPP) for dolutegravir, a key component of widely used HIV prevention drugs like Descovy and Dovato.This license allows generic manufacturers to produce and distribute affordable versions of these medications, specifically for the US market. The agreement focuses on making PrEP (pre-exposure prophylaxis) accessible to a wider population.
Currently, a year’s supply of PrEP can cost over $20,000 without insurance, creating a significant barrier to access. The MPP will sub-license to qualified generic manufacturers in the US, with the goal of bringing the annual cost down to around $40 per person by 2027. This price point is crucial for reaching underserved communities and achieving equitable access to HIV prevention.
Why This Matters: The PrEP Landscape and HIV Prevention
prep is highly effective in preventing HIV infection when taken as prescribed. Studies have shown a reduction of up to 99% in HIV transmission among individuals consistently using PrEP. Though, despite its efficacy, uptake has been hampered by cost, awareness, and access barriers. According to the Centers for Disease Control and Prevention (CDC), approximately 1.2 million people in the US could benefit from PrEP, but only a fraction currently have access.
The new agreement directly addresses the cost barrier. The $40 annual price point is comparable to the cost of PrEP in countries where generic versions are already available through MPP licensing agreements, such as South Africa. This demonstrates the potential for significant cost reduction through generic competition.
Timeline and Implementation
Here’s a breakdown of the key dates and steps:
- May 2024: Licensing agreement between ViiV Healthcare and the Medicines Patent Pool is announced.
- 2025-2027: MPP will sub-license to qualified generic manufacturers in the US. These manufacturers will work to obtain regulatory approvals from the Food and Drug Administration (FDA).
- 2027: Affordable generic PrEP is expected to become available in the US market, priced at approximately $40 per year.
The FDA approval process is a critical step. Generic manufacturers must demonstrate bioequivalence to the branded drugs to ensure efficacy and safety. The MPP will play a key role in facilitating this process and ensuring quality control.
Who is Affected?
This agreement will have a profound impact on several groups:
- Individuals at risk of HIV: Lowering the cost of PrEP will make it accessible to more people who could benefit from it, particularly those who are uninsured or underinsured.
- Public Health Agencies: Increased PrEP uptake will contribute to reducing new HIV infections, easing the burden on healthcare systems.
- Healthcare Providers: More affordable PrEP will allow providers to offer it as a standard of care to a wider range of patients.
- Pharmaceutical Industry: While ViiV Healthcare may see a decrease in revenue from branded PrEP sales, the agreement demonstrates a commitment to public health and responsible licensing.
Data and Statistics
| Metric | Current Status (2024) | Projected status (2027) |
|---|---|---|
| Annual Cost of PrEP (without insurance) | $20,000+ | $40 |